Related Experiment Videos
Pharmacokinetically induced benzodiazepine withdrawal
1Mood and Anxiety Disorders Program, Emory University School of Medicine in Atlanta, GA, USA. philninan@learnlink.emory.edu
Psychopharmacology Bulletin
|October 26, 2002
Summary
Discontinuing the antidepressant nefazodone can trigger benzodiazepine withdrawal. This occurs because nefazodone inhibits CYP3A4, and its removal increases alprazolam metabolism, leading to withdrawal symptoms.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Drug Interactions
Background:
- Pharmacokinetic interactions are crucial in managing patient drug regimens.
- Discontinuation of a concomitant medication can alter drug plasma levels and precipitate adverse events.
- Cytochrome P450 3A4 (CYP3A4) isoenzyme plays a significant role in drug metabolism.
Observation:
- A patient experienced benzodiazepine withdrawal symptoms upon cessation of nefazodone therapy.
- Nefazodone is known to inhibit the CYP3A4 isoenzyme.
- Concurrently, the patient was taking alprazolam, a known substrate of CYP3A4.
Findings:
- Discontinuation of nefazodone led to a rapid decrease in plasma alprazolam levels.
- This decrease is attributed to the presumed restoration of CYP3A4 activity, enhancing alprazolam metabolism.
- The patient exhibited clinical signs consistent with benzodiazepine withdrawal.
Implications:
- Clinicians must consider potential pharmacokinetic interactions when discontinuing medications, not just when initiating them.
- Anticipating and managing withdrawal symptoms is essential when stopping CYP3A4 inhibitors like nefazodone.
- This case highlights the importance of monitoring drug levels and patient symptoms during medication regimen changes.